Previous 10 | Next 10 |
Evofem recently launched the first new non-hormonal birth control option in decades. Clinical efficacy falls short of the copper IUD, PARAGARD, but that device I believe may come with significant side effects. A trend in birth control centered on the woman's quality of life (safet...
The following slide deck was published by TherapeuticsMD, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: TherapeuticsMD, Inc. 2020 Q4 - Results - Earnings Call Presentation
Ovid Therapeutics (OVID) +73% after soticlestat deal with Takeda.KemPharm (KMPH) +69% on FDA approval of ADHD drug.Ocugen, Inc. (OCGN) +39% on Indian partner’s COVID-19 vaccine efficacy data.Asensus Surgical (TRXC) +33% on FDA clearance for Senhance Surgical System....
Image source: The Motley Fool. TherapeuticsMD, Inc. (NASDAQ: TXMD) Q4 2020 Earnings Call Mar 02, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: TherapeuticsMD, Inc. (TXMD) Q4 2020 Earnings Call Transcript
TherapeuticsMD, Inc. (TXMD) Q4 2020 Earnings Conference Call March 2, 2021 08:30 ET Company Participants Nichol Ochsner - Vice President of Investor Relations Robert Finizio - Chief Executive Officer James D'Arecca - Chief Financial Officer Dawn Halkuff - Chief Commercial Officer Mitchell Kra...
Therapeutics MD (TXMD) posted fourth-quarter revenue that beat Wall Street estimates, driven by higher demand for its ANNOVERA system (segesterone acetate and ethinyl estradiol vaginal system).ANNOVERA net product revenue increased 42% to $9.1M for the fourth quarter of 2020 as compared...
Therapeutics MD (TXMD): Q4 GAAP EPS of -$0.15 misses by $0.05.Revenue of $22.6M (+42.1% Y/Y) beats by $0.89M.Shares +9.34% PM.Press Release For further details see: Therapeutics MD EPS misses by $0.05, beats on revenue
- Full-year 2020 total net product revenue increased 84% to $62.9 million compared to 2019 - - 4Q20 total net product revenue increased 30% to $22.6 million compared to 3Q20 - - ANNOVERA ® net product revenue increased 42% for 4Q20 compared to 3Q20 - - Financing Agr...
-Executive Management to Host Conference Call on March 2, 2021 at 8:30 a.m. ET- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its fourth quarter 2020 financial results on Tuesday, March 2, 2021, before t...
TherapeuticsMD (TXMD) has priced an underwritten public offering of 59.5 million shares for net proceeds of $110M.Proceeds to be used for commercialization of its three FDA-approved products, Imvexxy, Bijuva, and Annovera; partial proceeds also for offering to discharge certain indebtedness c...
News, Short Squeeze, Breakout and More Instantly...
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (...
• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023...